ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
In Vivo Reprogramming of Tissue-Derived Extracellular Vesicles for Treating Chronic Tissue Injury Through Metabolic Engineering.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic and Therapeutic Roles of Extracellular Vesicles in Chronic Kidney Disease: A Systematic Review.Journal of extracellular vesicles · 2026Pooled it
- Hypertension-Induced Renal Injury: From Pathophysiology to Therapeutic Perspectives.Biomedicines · 2026Review
- Targeted blockade of extracellular vesicles-mediated profibrotic vicious circle using EVs-based dual-drug delivery system to prevent liver fibrosis.Journal of nanobiotechnology · 2025Article
- In Vivo Reprogramming of Tissue-Derived Extracellular Vesicles for Treating Chronic Tissue Injury Through Metabolic Engineering.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Extracellular vesicles (EVs) have emerged as promising therapeutics for regenerative medicine, but the efficacy of current exogenous EV-based therapies for treating chronic tissue injury is still unsatisfactory. Exercise can affect skeletal muscle EV secretion and that this process regulates the systemic health-promoting role of exercise, suggesting that fine-tuning of endogenous tissue EV secretion may provide a new therapeutic avenue. Here, this work reports that in vivo reprogramming of EV secretion via metabolic engineering is a promising strategy for treating chronic diseases. Briefly, exercise enhanced mitochondrial metabolism and EV production in healthy skeletal muscles, and EVs from healthy skeletal muscles subjected to exercise or metabolic engineering (boosting mitochondrial biogenesis via AAV-mediated muscle-specific TFAM overexpression) exerted cellular protective effects in vitro. In injured skeletal muscles, in vivo metabolic engineering therapy could reprogram EV secretion patterns (reducing pathological EV compositions while increasing beneficial EV compositions) by regulating multiple EV biogenesis and cargo sorting pathways. Reprogrammed muscle-derived EVs could reach major organs and tissues via the circulation and then simultaneously attenuated multiple-tissue (e.g., muscle and kidney) injury in chronic kidney disease. This study highlights that in vivo reprogramming of tissue-derived EVs via a metabolic engineering approach is a potential strategy for treating diverse chronic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.